GCCL said Friday it has signed a memorandum of understanding (MOU) with Italian pharmaceutical firm VisMederi to collaborate on vaccine development research at the World Vaccine Congress 2026 in Washington, D.C.

The two companies agreed to explore joint projects across multiple stages of development, including research on vaccine candidates targeting high-risk pathogens. They will also cooperate in areas such as joint marketing and operational support, GCCL said.


The partnership will expand support for global vaccine development projects, including responses to infectious diseases and pandemics, leveraging the companies’ biosafety level 2 and 3 (BL2–3) research facilities and analytical capabilities.

Alessandro Manenti, Chief Development Officer (CDO) of VisMederi, said the agreement marks “an important milestone” in strengthening collaboration in the global vaccine market, based on the companies’ combined expertise and networks.

“We anticipate new collaborative opportunities across various markets with GCCL and are committed to expanding our joint efforts to support vaccine development projects,” he said.

GCCL CEO Cho Kwan-gu said vaccine development requires a strong understanding of regional regulations and operational environments, as well as reliable analytical support.

“This agreement strengthens our foundation for global cooperation in responding to emerging variants and future pandemics,” Cho said. “We will continue leveraging both companies’ expertise and networks to provide systematic and reliable services to vaccine development partners worldwide.”



출처 : KBR(https://www.koreabiomed.com)